Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04049227 · ClinicalTrials.gov registry record · Early Phase 1
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
A Early Phase 1 study of Endometrial Endometrioid Adenocarcinoma, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT04049227 is a Early Phase 1 study of Endometrial Endometrioid Adenocarcinoma that has completed, run by Northwestern University. The registered enrollment target is 27 participants, below the 277-participant average among 6 other Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04049227, a Early Phase 1 study of Endometrial Endometrioid Adenocarcinoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
This early phase I trial studies how well abemaciclib and letrozole work in treating patients with endometrial cancer and determines whether there are changes in patients' cancer cell biomarkers (a genetic feature or specific protein) for cell growth before and after treatment. Antihormone therapy with aromatase inhibitors, such as letrozole, may lessen the amount of estrogen made by the body. Abemaciclib blocks the activities of a class of proteins called cyclin-dependent kinase, which are involved in cell duplication. Giving letrozole and abemaciclib together may slow down cancer cell growth in patients with endometrial cancer.
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Abemaciclib
- PROCEDURE Therapeutic Conventional Surgery
Study Locations (2)
Illinois
- Northwestern University - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2023-05-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04049227
The ClinicalTrials.gov registry entry for NCT04049227 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 6 other Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Letrozole is the first listed.
NCT04049227 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04049227 about?
NCT04049227 is a clinical study titled "Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer". This early phase I trial studies how well abemaciclib and letrozole work in treating patients with endometrial cancer and determines whether there are changes in patients' cancer cell biomarkers (a genetic feature or specific protein) for cell growth before and after treatment. Antihormone therapy w...
What is the current status of trial NCT04049227?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2019-08-12. Estimated completion is 2023-05-15.
What conditions does trial NCT04049227 study?
This clinical trial studies the following conditions: Endometrial Endometrioid Adenocarcinoma.
What interventions are being tested in trial NCT04049227?
The interventions under investigation include: Letrozole (DRUG), Abemaciclib (DRUG), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT04049227?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04049227 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
-
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
RECRUITING · Phase 3
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
RECRUITING · Phase 1
-
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.